Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Benefit-risk assessment of long-acting beta2-agonists in asthma.

Drug safety - 1 Jan 2004

Jackson Catherine M, Lipworth Brian

Abstract excerpt

The use of a regular long-acting beta2-adrenoceptor agonists (beta2-agonists; LABA) is now established in asthma guidelines as the preferred option for second-line controller therapy in addition to inhaled corticosteroids. This has been driven by data showing beneficial effects of LABAs on exacerbation rates, in turn suggesting a putative corticosteroid-sparing effect. As LABAs are devoid of any clinically...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenergic beta-2 Receptor Agonists
Share to Adrenergic beta-Agonists
Share to Asthma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Delayed-Action Preparations

Share to Drug Tolerance

Share to Glucocorticoids

Share to Receptors, Adrenergic, beta-2

Source

Identifiers

PMID: 15003036
DOI: 10.2165/00002018-200427040-00003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Benefit-risk assessment of long-acting beta2-agonists in asthma.PMID 15003036Read ↗

Safety of long-acting beta-agonists in asthma: a review.Semantic proximity Read ↗

Controversies regarding long-acting β2-agonists.Semantic proximity Read ↗

Long-acting beta2-adrenoceptor agonists: a smart choice for asthma?Semantic proximity Read ↗

Safety and efficacy of beta agonists.Semantic proximity Read ↗

Adverse effects of beta-agonists.Semantic proximity Read ↗

Evaluating combination therapies for asthma: pros, cons, and comparative benefits.Semantic proximity Read ↗

β2 Agonists.Semantic proximity Read ↗

Molecular Mechanisms of Combination Therapy With Inhaled Corticosteroids and Long-Acting β-AgonistsSemantic proximity Read ↗

The beta-2 adrenergic receptor and its agonists.Semantic proximity Read ↗

Understanding how long‐acting β2‐adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids in asthma – an updateSemantic proximity Read ↗

Pharmacogenetics of beta2 adrenergic receptor agonists in asthma managementSemantic proximity Read ↗

A comparison of the molecular pharmacological properties of current short, long and ultra-long-acting β2-agonists used for asthma and COPD.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.